3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Stomach Neoplasms
3
Urinary Bladder Neoplasms
1
Squamous-Cell Non-Small-Cell Lung Cancer
1
Gastrointestinal Neoplasms
1
Esophageal Neoplasms
1
Adenocarcinoma
1
Interventions
Oxaliplatin
4
Leucovorin
4
Irinotecan
4
Fluorouracil
4
Capecitabine
3
Bevacizumab
3
cobimetinib
2
Tomography, X-Ray Computed
2
Surveys and Questionnaires
2
Standard of Care
2
Specimen Handling
2
Panitumumab
2
Magnetic Resonance Spectroscopy
2
Ketamine
2
Hydroxychloroquine
2
Cyclophosphamide
2
Cisplatin
2
ulixertinib
1
trifluridine tipiracil drug combination
1
trastuzumab deruxtecan
1
tivozanib
1
sodium thiosulfate
1
rucaparib
1
romiplostim
1
rilotumumab
1
regorafenib
1
pralsetinib
1
ponatinib
1
pembrolizumab
1
osimertinib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Has results
×
Gastrointestinal Neoplasms
×
bemarituzumab
×
Clear all
NCT03343301
2024-02-28
FIGHT
Five Prime Therapeutics, Inc.
Phase 1
Completed
12 enrolled
17 charts